| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 81 | 2024 | 1963 | 8.440 |
Why?
|
| Brain Neoplasms | 120 | 2024 | 4849 | 7.470 |
Why?
|
| Glioblastoma | 66 | 2024 | 1797 | 6.380 |
Why?
|
| Oncolytic Viruses | 19 | 2024 | 204 | 5.080 |
Why?
|
| Oncolytic Virotherapy | 23 | 2024 | 280 | 4.650 |
Why?
|
| Neoplastic Stem Cells | 32 | 2021 | 1443 | 2.600 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 7 | 2020 | 204 | 2.270 |
Why?
|
| Adenoviridae | 25 | 2024 | 1459 | 2.030 |
Why?
|
| Exosomes | 3 | 2024 | 253 | 1.780 |
Why?
|
| Neurosurgical Procedures | 9 | 2020 | 609 | 1.290 |
Why?
|
| Mice, Nude | 42 | 2021 | 4307 | 1.270 |
Why?
|
| MicroRNAs | 8 | 2024 | 2947 | 1.080 |
Why?
|
| Cell Line, Tumor | 63 | 2024 | 14551 | 1.080 |
Why?
|
| Animals | 94 | 2024 | 59536 | 0.930 |
Why?
|
| Pinealoma | 2 | 2022 | 49 | 0.890 |
Why?
|
| Perioperative Care | 2 | 2020 | 451 | 0.880 |
Why?
|
| Mice | 75 | 2024 | 34495 | 0.870 |
Why?
|
| Xenograft Model Antitumor Assays | 25 | 2022 | 3821 | 0.860 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2023 | 7702 | 0.850 |
Why?
|
| Language | 3 | 2020 | 309 | 0.850 |
Why?
|
| Humans | 196 | 2024 | 261506 | 0.830 |
Why?
|
| Brain Ischemia | 1 | 2024 | 292 | 0.780 |
Why?
|
| Gene Expression Regulation, Neoplastic | 30 | 2024 | 8873 | 0.780 |
Why?
|
| Aphasia, Broca | 1 | 2020 | 5 | 0.760 |
Why?
|
| Neurosurgery | 3 | 2014 | 108 | 0.750 |
Why?
|
| Drug Evaluation | 1 | 2020 | 425 | 0.750 |
Why?
|
| Tropism | 3 | 2017 | 19 | 0.720 |
Why?
|
| Cerebral Cortex | 5 | 2018 | 621 | 0.720 |
Why?
|
| Genetic Therapy | 7 | 2017 | 1616 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2023 | 10035 | 0.690 |
Why?
|
| Chromosomes, Human, Pair 19 | 4 | 2014 | 143 | 0.690 |
Why?
|
| Motor Cortex | 1 | 2020 | 117 | 0.680 |
Why?
|
| Drug Delivery Systems | 4 | 2019 | 669 | 0.670 |
Why?
|
| STAT3 Transcription Factor | 7 | 2015 | 1121 | 0.660 |
Why?
|
| Cell Proliferation | 22 | 2023 | 7226 | 0.640 |
Why?
|
| Apoptosis | 20 | 2021 | 7591 | 0.630 |
Why?
|
| Cerebral Ventricle Neoplasms | 4 | 2023 | 81 | 0.620 |
Why?
|
| Oligodendroglioma | 2 | 2009 | 106 | 0.620 |
Why?
|
| Neural Stem Cells | 2 | 2018 | 181 | 0.610 |
Why?
|
| Radiation, Ionizing | 2 | 2017 | 187 | 0.590 |
Why?
|
| Oligopeptides | 6 | 2024 | 429 | 0.590 |
Why?
|
| Craniotomy | 7 | 2014 | 304 | 0.570 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2015 | 157 | 0.570 |
Why?
|
| Cell Differentiation | 14 | 2018 | 4078 | 0.540 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2015 | 24 | 0.530 |
Why?
|
| Seizures | 3 | 2013 | 989 | 0.520 |
Why?
|
| Tumor Microenvironment | 13 | 2023 | 2864 | 0.500 |
Why?
|
| Tumor Cells, Cultured | 19 | 2019 | 5395 | 0.500 |
Why?
|
| Astrocytoma | 7 | 2022 | 321 | 0.490 |
Why?
|
| Male | 76 | 2023 | 123000 | 0.490 |
Why?
|
| Receptor, TIE-2 | 4 | 2017 | 82 | 0.490 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 1360 | 0.490 |
Why?
|
| Transplantation, Heterologous | 12 | 2017 | 1082 | 0.470 |
Why?
|
| Blotting, Western | 15 | 2017 | 3536 | 0.460 |
Why?
|
| Integrins | 4 | 2021 | 262 | 0.460 |
Why?
|
| Proteome | 5 | 2017 | 561 | 0.450 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2023 | 2359 | 0.450 |
Why?
|
| Disease Models, Animal | 14 | 2019 | 7222 | 0.450 |
Why?
|
| Flow Cytometry | 13 | 2017 | 3033 | 0.450 |
Why?
|
| Transforming Growth Factor beta | 3 | 2021 | 1130 | 0.450 |
Why?
|
| Interleukin-6 | 2 | 2015 | 1038 | 0.440 |
Why?
|
| Phenytoin | 1 | 2013 | 71 | 0.440 |
Why?
|
| Pineal Gland | 2 | 2010 | 50 | 0.440 |
Why?
|
| Genes, p53 | 5 | 2018 | 1090 | 0.430 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2009 | 3552 | 0.430 |
Why?
|
| Congresses as Topic | 1 | 2014 | 298 | 0.430 |
Why?
|
| Cell Movement | 8 | 2018 | 2466 | 0.430 |
Why?
|
| Radiosurgery | 10 | 2017 | 1330 | 0.420 |
Why?
|
| Antineoplastic Agents | 18 | 2022 | 14289 | 0.410 |
Why?
|
| Infusions, Intra-Arterial | 4 | 2024 | 171 | 0.380 |
Why?
|
| Bone Marrow | 2 | 2021 | 2358 | 0.370 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 121 | 0.370 |
Why?
|
| Cerebral Arteries | 1 | 2010 | 73 | 0.370 |
Why?
|
| Immunotherapy | 6 | 2023 | 3341 | 0.360 |
Why?
|
| Serine | 2 | 2009 | 388 | 0.360 |
Why?
|
| Nerve Tissue Proteins | 5 | 2016 | 1491 | 0.360 |
Why?
|
| Glycoproteins | 4 | 2020 | 747 | 0.360 |
Why?
|
| Adult | 44 | 2022 | 77950 | 0.350 |
Why?
|
| Neoplasm Transplantation | 11 | 2021 | 1519 | 0.350 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 106 | 0.350 |
Why?
|
| Anticonvulsants | 1 | 2013 | 431 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2009 | 327 | 0.340 |
Why?
|
| HSP90 Heat-Shock Proteins | 4 | 2022 | 196 | 0.330 |
Why?
|
| Female | 59 | 2023 | 141928 | 0.330 |
Why?
|
| Middle Aged | 45 | 2023 | 86204 | 0.330 |
Why?
|
| Brain | 8 | 2020 | 4113 | 0.320 |
Why?
|
| Young Adult | 20 | 2022 | 21445 | 0.320 |
Why?
|
| Skull | 1 | 2010 | 231 | 0.320 |
Why?
|
| Patient Positioning | 1 | 2010 | 195 | 0.320 |
Why?
|
| Societies, Medical | 1 | 2014 | 1335 | 0.310 |
Why?
|
| Threonine | 1 | 2008 | 161 | 0.310 |
Why?
|
| Signal Transduction | 17 | 2020 | 11965 | 0.310 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2024 | 480 | 0.300 |
Why?
|
| Supratentorial Neoplasms | 3 | 2013 | 78 | 0.290 |
Why?
|
| Cell Separation | 4 | 2012 | 612 | 0.290 |
Why?
|
| Treatment Outcome | 23 | 2022 | 32848 | 0.290 |
Why?
|
| Injections, Intra-Arterial | 4 | 2021 | 62 | 0.290 |
Why?
|
| Pyrans | 2 | 2016 | 20 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 12 | 2023 | 6942 | 0.280 |
Why?
|
| Autophagy | 6 | 2017 | 927 | 0.280 |
Why?
|
| Cells, Cultured | 7 | 2020 | 5637 | 0.270 |
Why?
|
| Gene Expression Profiling | 11 | 2023 | 5159 | 0.270 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 846 | 0.270 |
Why?
|
| Molecular Imaging | 2 | 2018 | 185 | 0.270 |
Why?
|
| Survival Rate | 13 | 2019 | 12221 | 0.260 |
Why?
|
| Dacarbazine | 3 | 2017 | 485 | 0.260 |
Why?
|
| Antigens, CD | 5 | 2020 | 1385 | 0.260 |
Why?
|
| Eye Proteins | 2 | 2005 | 269 | 0.260 |
Why?
|
| Esotropia | 1 | 2005 | 54 | 0.260 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 1005 | 0.260 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2015 | 123 | 0.250 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2005 | 43 | 0.250 |
Why?
|
| Hospitals, University | 1 | 2005 | 209 | 0.250 |
Why?
|
| Blood-Brain Barrier | 4 | 2022 | 238 | 0.250 |
Why?
|
| Adenoviridae Infections | 2 | 2023 | 125 | 0.250 |
Why?
|
| Carotid Artery, External | 1 | 2024 | 14 | 0.250 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2016 | 107 | 0.250 |
Why?
|
| Sirolimus | 2 | 2008 | 814 | 0.240 |
Why?
|
| Virus Replication | 3 | 2021 | 709 | 0.240 |
Why?
|
| Repressor Proteins | 5 | 2019 | 1664 | 0.240 |
Why?
|
| Neoplasm Grading | 4 | 2020 | 1742 | 0.240 |
Why?
|
| Aged | 33 | 2020 | 70117 | 0.240 |
Why?
|
| Aquaporins | 1 | 2023 | 23 | 0.240 |
Why?
|
| Neoplasms | 7 | 2021 | 15193 | 0.240 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2017 | 624 | 0.240 |
Why?
|
| Carotid Artery, Internal | 1 | 2024 | 77 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 11 | 2023 | 3981 | 0.230 |
Why?
|
| Carotid Artery, Common | 1 | 2024 | 91 | 0.230 |
Why?
|
| Glioma, Subependymal | 1 | 2023 | 25 | 0.230 |
Why?
|
| HEK293 Cells | 3 | 2024 | 1489 | 0.230 |
Why?
|
| Cancer Vaccines | 2 | 2020 | 697 | 0.230 |
Why?
|
| Adenovirus E1A Proteins | 4 | 2009 | 163 | 0.230 |
Why?
|
| Gene Expression | 6 | 2018 | 3570 | 0.230 |
Why?
|
| Injections, Intralesional | 3 | 2018 | 164 | 0.230 |
Why?
|
| Genetic Vectors | 6 | 2009 | 1694 | 0.230 |
Why?
|
| Brain Mapping | 4 | 2020 | 644 | 0.230 |
Why?
|
| Biomarkers, Tumor | 11 | 2024 | 10331 | 0.220 |
Why?
|
| Wakefulness | 3 | 2014 | 150 | 0.220 |
Why?
|
| Microsurgery | 1 | 2005 | 244 | 0.220 |
Why?
|
| Carotid Arteries | 1 | 2024 | 240 | 0.220 |
Why?
|
| Dexamethasone | 2 | 2018 | 1450 | 0.220 |
Why?
|
| Drug Synergism | 4 | 2020 | 1313 | 0.220 |
Why?
|
| Adolescent | 16 | 2022 | 31252 | 0.220 |
Why?
|
| Rabbits | 1 | 2024 | 957 | 0.210 |
Why?
|
| Leukemia | 1 | 2011 | 1635 | 0.210 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 500 | 0.210 |
Why?
|
| Isoindoles | 2 | 2022 | 11 | 0.210 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2022 | 57 | 0.210 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2015 | 278 | 0.210 |
Why?
|
| Stem Cells | 4 | 2024 | 1213 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2014 | 1423 | 0.210 |
Why?
|
| NAD | 1 | 2022 | 89 | 0.210 |
Why?
|
| Cell Cycle | 5 | 2012 | 2084 | 0.210 |
Why?
|
| Lipoproteins | 1 | 2003 | 252 | 0.200 |
Why?
|
| Mesocricetus | 1 | 2021 | 114 | 0.200 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 2021 | 6 | 0.200 |
Why?
|
| Heterografts | 6 | 2021 | 733 | 0.200 |
Why?
|
| Prospective Studies | 8 | 2021 | 12873 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 224 | 0.200 |
Why?
|
| Brain Stem Neoplasms | 1 | 2022 | 108 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 726 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 502 | 0.200 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 29902 | 0.200 |
Why?
|
| Antigens, Neoplasm | 3 | 2023 | 1506 | 0.200 |
Why?
|
| X-linked Nuclear Protein | 2 | 2018 | 56 | 0.190 |
Why?
|
| Nanomedicine | 1 | 2020 | 54 | 0.190 |
Why?
|
| Lipid Peroxidation | 1 | 2021 | 157 | 0.190 |
Why?
|
| Broca Area | 1 | 2020 | 7 | 0.190 |
Why?
|
| Cricetinae | 1 | 2021 | 706 | 0.190 |
Why?
|
| Retrospective Studies | 20 | 2023 | 37905 | 0.190 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 545 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 3 | 2014 | 89 | 0.180 |
Why?
|
| Cell Self Renewal | 2 | 2020 | 62 | 0.180 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 233 | 0.180 |
Why?
|
| CLOCK Proteins | 1 | 2020 | 35 | 0.180 |
Why?
|
| ARNTL Transcription Factors | 1 | 2020 | 57 | 0.180 |
Why?
|
| Endpoint Determination | 1 | 2020 | 176 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 2 | 2023 | 577 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 1586 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 1581 | 0.180 |
Why?
|
| Prognosis | 17 | 2023 | 21713 | 0.180 |
Why?
|
| Cell Survival | 9 | 2020 | 3045 | 0.180 |
Why?
|
| Biological Therapy | 1 | 2019 | 58 | 0.170 |
Why?
|
| Karnofsky Performance Status | 5 | 2014 | 175 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 201 | 0.170 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2019 | 63 | 0.170 |
Why?
|
| Phosphorylation | 6 | 2017 | 4804 | 0.170 |
Why?
|
| Multivesicular Bodies | 1 | 2018 | 6 | 0.170 |
Why?
|
| Docosahexaenoic Acids | 2 | 2018 | 79 | 0.160 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 60 | 0.160 |
Why?
|
| Intracellular Membranes | 1 | 2018 | 108 | 0.160 |
Why?
|
| ErbB Receptors | 5 | 2023 | 2295 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2022 | 62 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2022 | 534 | 0.160 |
Why?
|
| Third Ventricle | 2 | 2010 | 37 | 0.160 |
Why?
|
| Cerebral Veins | 1 | 2018 | 28 | 0.160 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 470 | 0.160 |
Why?
|
| Mutation | 8 | 2024 | 15179 | 0.160 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 149 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 3719 | 0.160 |
Why?
|
| Magnetite Nanoparticles | 1 | 2018 | 50 | 0.160 |
Why?
|
| Caveolae | 1 | 2017 | 20 | 0.160 |
Why?
|
| Postoperative Care | 2 | 2020 | 739 | 0.160 |
Why?
|
| Glycomics | 2 | 2015 | 27 | 0.160 |
Why?
|
| AC133 Antigen | 3 | 2012 | 110 | 0.150 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 598 | 0.150 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2016 | 204 | 0.150 |
Why?
|
| Melanoma | 4 | 2023 | 5317 | 0.150 |
Why?
|
| Photoacoustic Techniques | 1 | 2018 | 54 | 0.150 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2017 | 71 | 0.150 |
Why?
|
| Fluorescent Dyes | 3 | 2011 | 459 | 0.150 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 591 | 0.150 |
Why?
|
| Exotoxins | 2 | 2007 | 77 | 0.150 |
Why?
|
| Podosomes | 1 | 2016 | 2 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2018 | 1823 | 0.150 |
Why?
|
| Interleukin-13 | 2 | 2007 | 135 | 0.150 |
Why?
|
| Mass Spectrometry | 3 | 2015 | 702 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2017 | 731 | 0.150 |
Why?
|
| Phosphatidylserines | 1 | 2017 | 68 | 0.140 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 14889 | 0.140 |
Why?
|
| Microscopy, Electron | 1 | 2017 | 600 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 53 | 0.140 |
Why?
|
| Spinal Neoplasms | 2 | 2014 | 631 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3230 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 2 | 2015 | 778 | 0.140 |
Why?
|
| Peptides | 3 | 2012 | 1479 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 6 | 2017 | 3101 | 0.140 |
Why?
|
| Mitochondria | 2 | 2021 | 1282 | 0.140 |
Why?
|
| Caveolin 1 | 1 | 2017 | 204 | 0.140 |
Why?
|
| Cell Membrane | 2 | 2018 | 850 | 0.140 |
Why?
|
| Nervous System Neoplasms | 2 | 2006 | 36 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 203 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 15862 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 462 | 0.140 |
Why?
|
| Benzamides | 2 | 2022 | 1832 | 0.140 |
Why?
|
| Monitoring, Intraoperative | 2 | 2014 | 264 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 1489 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2016 | 79 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 904 | 0.140 |
Why?
|
| raf Kinases | 1 | 2016 | 81 | 0.140 |
Why?
|
| Lysosomes | 1 | 2018 | 347 | 0.140 |
Why?
|
| Phosphatidic Acids | 1 | 2015 | 16 | 0.130 |
Why?
|
| Extracellular Vesicles | 1 | 2017 | 135 | 0.130 |
Why?
|
| Transduction, Genetic | 2 | 2009 | 475 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 726 | 0.130 |
Why?
|
| Diglycerides | 1 | 2015 | 37 | 0.130 |
Why?
|
| Transcriptome | 5 | 2015 | 1859 | 0.130 |
Why?
|
| NF-kappa B | 3 | 2013 | 1549 | 0.130 |
Why?
|
| Protein Transport | 4 | 2018 | 734 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2012 | 448 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.130 |
Why?
|
| Camptothecin | 2 | 2009 | 517 | 0.130 |
Why?
|
| DNA Damage | 3 | 2016 | 1954 | 0.130 |
Why?
|
| Staining and Labeling | 2 | 2018 | 429 | 0.130 |
Why?
|
| Immunity, Innate | 2 | 2021 | 677 | 0.120 |
Why?
|
| Time Factors | 8 | 2017 | 12926 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 3 | 2018 | 694 | 0.120 |
Why?
|
| Tyrosine | 1 | 2016 | 498 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2013 | 622 | 0.120 |
Why?
|
| Polysaccharides | 1 | 2015 | 197 | 0.120 |
Why?
|
| Immune Tolerance | 3 | 2013 | 403 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1375 | 0.120 |
Why?
|
| Sella Turcica | 1 | 2013 | 24 | 0.120 |
Why?
|
| Sphenoid Bone | 1 | 2013 | 22 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2017 | 9244 | 0.120 |
Why?
|
| Radiation Tolerance | 2 | 2016 | 629 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2023 | 2819 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 371 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 487 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 99 | 0.120 |
Why?
|
| Mesoderm | 1 | 2015 | 404 | 0.110 |
Why?
|
| Epigenomics | 2 | 2011 | 266 | 0.110 |
Why?
|
| Child, Preschool | 7 | 2022 | 16273 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2011 | 786 | 0.110 |
Why?
|
| rho Guanine Nucleotide Dissociation Inhibitor alpha | 1 | 2013 | 19 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 516 | 0.110 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2013 | 42 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2017 | 2231 | 0.110 |
Why?
|
| Nestin | 1 | 2012 | 42 | 0.110 |
Why?
|
| Cell Adhesion | 3 | 2016 | 1008 | 0.110 |
Why?
|
| Republic of Korea | 1 | 2012 | 70 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 3 | 2011 | 1547 | 0.110 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 81 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 541 | 0.110 |
Why?
|
| Diagnosis, Differential | 5 | 2010 | 4744 | 0.110 |
Why?
|
| Genetic Engineering | 2 | 2005 | 288 | 0.110 |
Why?
|
| Survival Analysis | 8 | 2017 | 9180 | 0.110 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 442 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 588 | 0.110 |
Why?
|
| Macrophages | 2 | 2020 | 1304 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2014 | 441 | 0.110 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1656 | 0.110 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 195 | 0.100 |
Why?
|
| Angiopoietin-2 | 2 | 2016 | 38 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 301 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1620 | 0.100 |
Why?
|
| Cognition | 2 | 2009 | 968 | 0.100 |
Why?
|
| Cyanoacrylates | 1 | 2012 | 41 | 0.100 |
Why?
|
| Phosphoproteins | 3 | 2018 | 1152 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 574 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1064 | 0.100 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2009 | 75 | 0.100 |
Why?
|
| Integrin beta Chains | 1 | 2011 | 34 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2011 | 56 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2013 | 229 | 0.100 |
Why?
|
| Amino Acids | 1 | 2014 | 728 | 0.100 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 203 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 840 | 0.100 |
Why?
|
| Gene Fusion | 1 | 2013 | 209 | 0.100 |
Why?
|
| RNA, Messenger | 5 | 2015 | 6150 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 987 | 0.100 |
Why?
|
| DNA Methylation | 4 | 2017 | 2669 | 0.100 |
Why?
|
| Ependymoma | 1 | 2013 | 242 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2015 | 612 | 0.100 |
Why?
|
| Transfection | 4 | 2010 | 2944 | 0.100 |
Why?
|
| Histones | 2 | 2016 | 1466 | 0.100 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 1399 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2013 | 1021 | 0.100 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 215 | 0.100 |
Why?
|
| Preoperative Period | 3 | 2020 | 344 | 0.100 |
Why?
|
| G2 Phase | 1 | 2011 | 206 | 0.100 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 156 | 0.100 |
Why?
|
| Phenotype | 7 | 2023 | 6295 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2014 | 383 | 0.090 |
Why?
|
| Melanoma, Experimental | 3 | 2019 | 368 | 0.090 |
Why?
|
| Pyridones | 1 | 2013 | 348 | 0.090 |
Why?
|
| Frasier Syndrome | 1 | 2009 | 8 | 0.090 |
Why?
|
| Gonadoblastoma | 1 | 2009 | 9 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1763 | 0.090 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 3869 | 0.090 |
Why?
|
| Dysgerminoma | 1 | 2009 | 42 | 0.090 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2009 | 21 | 0.090 |
Why?
|
| Cerebral Ventricles | 1 | 2010 | 98 | 0.090 |
Why?
|
| Biopsy | 1 | 2018 | 3443 | 0.090 |
Why?
|
| Carcinogenesis | 3 | 2023 | 1026 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2010 | 80 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 2326 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 2370 | 0.090 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2009 | 11 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2011 | 2314 | 0.090 |
Why?
|
| Cranial Irradiation | 2 | 2009 | 315 | 0.090 |
Why?
|
| Genes, Wilms Tumor | 1 | 2009 | 64 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 528 | 0.090 |
Why?
|
| Mice, SCID | 2 | 2011 | 1869 | 0.090 |
Why?
|
| RNA Splice Sites | 1 | 2009 | 111 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 1073 | 0.090 |
Why?
|
| Corpus Callosum | 1 | 2010 | 138 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2008 | 7548 | 0.090 |
Why?
|
| Gelatinases | 1 | 2009 | 52 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 1217 | 0.090 |
Why?
|
| Verbal Learning | 1 | 2009 | 84 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2008 | 1062 | 0.080 |
Why?
|
| Combined Modality Therapy | 7 | 2022 | 8865 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 3203 | 0.080 |
Why?
|
| Histone Demethylases | 2 | 2023 | 144 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 622 | 0.080 |
Why?
|
| Thromboplastin | 1 | 2008 | 34 | 0.080 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 6089 | 0.080 |
Why?
|
| Peptides, Cyclic | 1 | 2009 | 139 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 3022 | 0.080 |
Why?
|
| Postoperative Complications | 4 | 2010 | 5542 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 2508 | 0.080 |
Why?
|
| Radiotherapy Dosage | 4 | 2015 | 3842 | 0.080 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 11538 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 6207 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 376 | 0.080 |
Why?
|
| Extracellular Matrix | 2 | 2011 | 554 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 598 | 0.080 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2009 | 221 | 0.080 |
Why?
|
| Iron | 1 | 2010 | 376 | 0.080 |
Why?
|
| Loss of Heterozygosity | 2 | 2006 | 602 | 0.080 |
Why?
|
| Genes, p16 | 1 | 2007 | 125 | 0.080 |
Why?
|
| HeLa Cells | 3 | 2018 | 1643 | 0.080 |
Why?
|
| Infusions, Intralesional | 2 | 2022 | 9 | 0.070 |
Why?
|
| Galectin 1 | 1 | 2007 | 20 | 0.070 |
Why?
|
| Zebrafish | 2 | 2022 | 463 | 0.070 |
Why?
|
| Osteosarcoma | 1 | 2014 | 929 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2011 | 825 | 0.070 |
Why?
|
| Convection | 2 | 2022 | 6 | 0.070 |
Why?
|
| Fatty Acids | 2 | 2021 | 448 | 0.070 |
Why?
|
| Point Mutation | 1 | 2009 | 769 | 0.070 |
Why?
|
| Immunomodulation | 2 | 2019 | 242 | 0.070 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 2045 | 0.070 |
Why?
|
| Procarbazine | 1 | 2006 | 69 | 0.070 |
Why?
|
| Immunotoxins | 1 | 2007 | 117 | 0.070 |
Why?
|
| Lomustine | 1 | 2006 | 39 | 0.070 |
Why?
|
| E2F1 Transcription Factor | 1 | 2007 | 206 | 0.070 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2006 | 26 | 0.070 |
Why?
|
| Integrin beta1 | 1 | 2006 | 126 | 0.070 |
Why?
|
| Memory | 1 | 2009 | 429 | 0.070 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2006 | 57 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2011 | 5270 | 0.070 |
Why?
|
| Proteomics | 2 | 2017 | 1380 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 1724 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4757 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 943 | 0.070 |
Why?
|
| Incidence | 2 | 2013 | 5673 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 39 | 0.070 |
Why?
|
| Lipids | 1 | 2009 | 644 | 0.070 |
Why?
|
| Laminectomy | 1 | 2005 | 52 | 0.070 |
Why?
|
| Immunoblotting | 3 | 2015 | 886 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2022 | 1129 | 0.060 |
Why?
|
| Neuroglia | 1 | 2006 | 223 | 0.060 |
Why?
|
| Protein Isoforms | 3 | 2014 | 842 | 0.060 |
Why?
|
| Dura Mater | 1 | 2005 | 73 | 0.060 |
Why?
|
| Interferon-beta | 1 | 2005 | 102 | 0.060 |
Why?
|
| Pyridines | 1 | 2012 | 1244 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1303 | 0.060 |
Why?
|
| Oxygen | 1 | 2009 | 754 | 0.060 |
Why?
|
| Patient Selection | 3 | 2014 | 2055 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 135 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 3639 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 447 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 383 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 143 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1945 | 0.060 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2004 | 22 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2004 | 255 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1869 | 0.060 |
Why?
|
| Myoblasts | 1 | 2004 | 72 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 256 | 0.060 |
Why?
|
| Rats | 1 | 2013 | 6086 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2007 | 3890 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 2014 | 4233 | 0.060 |
Why?
|
| Fourth Ventricle | 1 | 2023 | 51 | 0.060 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 2 | 2013 | 25 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 243 | 0.060 |
Why?
|
| Hippocalcin | 1 | 2003 | 13 | 0.060 |
Why?
|
| Trypan Blue | 1 | 2003 | 14 | 0.060 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2023 | 36 | 0.060 |
Why?
|
| Recoverin | 1 | 2003 | 22 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 181 | 0.060 |
Why?
|
| Viruses | 1 | 2005 | 159 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4143 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 360 | 0.060 |
Why?
|
| Protein Binding | 3 | 2016 | 3438 | 0.060 |
Why?
|
| Texas | 3 | 2014 | 6311 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 4988 | 0.060 |
Why?
|
| fas Receptor | 1 | 2004 | 185 | 0.060 |
Why?
|
| Telomerase | 1 | 2006 | 525 | 0.060 |
Why?
|
| Etoposide | 1 | 2005 | 870 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 4654 | 0.050 |
Why?
|
| Base Sequence | 4 | 2013 | 4917 | 0.050 |
Why?
|
| Logistic Models | 3 | 2020 | 3441 | 0.050 |
Why?
|
| Down-Regulation | 3 | 2016 | 2074 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 4053 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2003 | 234 | 0.050 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 113 | 0.050 |
Why?
|
| Perceptual Disorders | 1 | 2002 | 14 | 0.050 |
Why?
|
| Chaperonins | 1 | 2022 | 27 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 1533 | 0.050 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2022 | 20 | 0.050 |
Why?
|
| Stereotaxic Techniques | 3 | 2013 | 172 | 0.050 |
Why?
|
| Kynurenine | 1 | 2022 | 71 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2018 | 837 | 0.050 |
Why?
|
| Vincristine | 1 | 2006 | 1511 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 7551 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 69 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2009 | 1411 | 0.050 |
Why?
|
| Carmustine | 1 | 2002 | 214 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 343 | 0.050 |
Why?
|
| Retinoblastoma | 1 | 2003 | 200 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 852 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 1648 | 0.050 |
Why?
|
| Necrosis | 2 | 2016 | 580 | 0.050 |
Why?
|
| Monocytes | 2 | 2016 | 788 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2017 | 875 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2016 | 289 | 0.050 |
Why?
|
| Forkhead Box Protein M1 | 2 | 2015 | 113 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 323 | 0.050 |
Why?
|
| Electric Stimulation | 2 | 2014 | 426 | 0.050 |
Why?
|
| Radiotherapy, Conformal | 2 | 2007 | 902 | 0.050 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2020 | 27 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 264 | 0.050 |
Why?
|
| Apyrase | 1 | 2020 | 44 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2022 | 311 | 0.050 |
Why?
|
| Binding Sites | 2 | 2016 | 2171 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1944 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 61 | 0.050 |
Why?
|
| Perfusion | 1 | 2021 | 293 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3251 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 418 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2017 | 1987 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2004 | 436 | 0.050 |
Why?
|
| Speech Disorders | 2 | 2011 | 91 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 269 | 0.050 |
Why?
|
| Genomics | 2 | 2024 | 2738 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 6009 | 0.050 |
Why?
|
| Protein Stability | 2 | 2013 | 370 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2010 | 2022 | 0.050 |
Why?
|
| Niacinamide | 1 | 2022 | 421 | 0.050 |
Why?
|
| Cyclin D1 | 2 | 2017 | 576 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 584 | 0.050 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 314 | 0.050 |
Why?
|
| Nervous System Diseases | 3 | 2009 | 500 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4557 | 0.040 |
Why?
|
| Acute Disease | 1 | 2005 | 2422 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Astrocytes | 1 | 2003 | 368 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2005 | 540 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2017 | 2450 | 0.040 |
Why?
|
| Tumor Escape | 2 | 2013 | 251 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2004 | 486 | 0.040 |
Why?
|
| Morbidity | 2 | 2011 | 397 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2018 | 621 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 986 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 208 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5061 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 1143 | 0.040 |
Why?
|
| Research Design | 1 | 2006 | 1544 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 264 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 1155 | 0.040 |
Why?
|
| Cytokines | 2 | 2022 | 2809 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 716 | 0.040 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cell-Free System | 1 | 2018 | 150 | 0.040 |
Why?
|
| Biological Variation, Individual | 1 | 2018 | 4 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Neuroepithelial Cells | 1 | 2018 | 13 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 314 | 0.040 |
Why?
|
| Microglia | 1 | 2020 | 164 | 0.040 |
Why?
|
| Chemokines | 2 | 2010 | 314 | 0.040 |
Why?
|
| Ion Transport | 1 | 2018 | 79 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 621 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2011 | 665 | 0.040 |
Why?
|
| Hyperemia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Synapses | 1 | 2022 | 509 | 0.040 |
Why?
|
| Autophagy-Related Protein 5 | 2 | 2008 | 46 | 0.040 |
Why?
|
| Models, Animal | 1 | 2020 | 664 | 0.040 |
Why?
|
| RNA Interference | 2 | 2013 | 1408 | 0.040 |
Why?
|
| Particle Size | 1 | 2018 | 182 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 2594 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 1016 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2018 | 79 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 419 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2002 | 803 | 0.040 |
Why?
|
| Symporters | 1 | 2018 | 98 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2010 | 368 | 0.040 |
Why?
|
| OX40 Ligand | 1 | 2017 | 28 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 4821 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 116 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 164 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 124 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 1320 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 482 | 0.040 |
Why?
|
| United States | 1 | 2014 | 15433 | 0.040 |
Why?
|
| Biological Transport | 1 | 2018 | 597 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 244 | 0.040 |
Why?
|
| Neurons | 2 | 2005 | 2287 | 0.040 |
Why?
|
| Child | 6 | 2022 | 29154 | 0.040 |
Why?
|
| Hemianopsia | 2 | 2009 | 42 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 409 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2009 | 245 | 0.030 |
Why?
|
| Angiotensin I | 1 | 2016 | 18 | 0.030 |
Why?
|
| Biological Products | 1 | 2019 | 274 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 582 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2007 | 187 | 0.030 |
Why?
|
| Gold | 1 | 2018 | 270 | 0.030 |
Why?
|
| Dependovirus | 1 | 2017 | 135 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 133 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2019 | 938 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 252 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 905 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 157 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 663 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 115 | 0.030 |
Why?
|
| Mannose | 1 | 2015 | 40 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 126 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2018 | 287 | 0.030 |
Why?
|
| Tranylcypromine | 1 | 2015 | 10 | 0.030 |
Why?
|
| DNA End-Joining Repair | 1 | 2016 | 86 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2016 | 172 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 1914 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 2139 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 460 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 213 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 198 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 2216 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Photomicrography | 1 | 2014 | 26 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 1688 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 483 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 4298 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 237 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 476 | 0.030 |
Why?
|
| Cell Line | 2 | 2018 | 5114 | 0.030 |
Why?
|
| Cisplatin | 1 | 2002 | 2432 | 0.030 |
Why?
|
| Hybridomas | 1 | 2014 | 75 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 592 | 0.030 |
Why?
|
| Microbiota | 1 | 2020 | 547 | 0.030 |
Why?
|
| DNA Repair | 1 | 2022 | 1872 | 0.030 |
Why?
|
| Ohio | 1 | 2014 | 113 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 78 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2009 | 1618 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 148 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2014 | 196 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 875 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 1271 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 4892 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 342 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2014 | 129 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2015 | 434 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 292 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2012 | 100 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2013 | 108 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 210 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 2307 | 0.030 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2012 | 18 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 249 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2013 | 201 | 0.030 |
Why?
|
| DNA Primers | 2 | 2005 | 1399 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2013 | 198 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2018 | 1048 | 0.030 |
Why?
|
| Kinetics | 2 | 2006 | 2049 | 0.030 |
Why?
|
| Lectins | 1 | 2012 | 151 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2011 | 62 | 0.030 |
Why?
|
| Quality of Life | 2 | 2022 | 4532 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 1555 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 1439 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2009 | 1178 | 0.030 |
Why?
|
| Adipokines | 1 | 2012 | 96 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 2315 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 249 | 0.030 |
Why?
|
| Contrast Media | 1 | 2018 | 1472 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 760 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 222 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2010 | 45 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 1085 | 0.020 |
Why?
|
| Transferrin | 1 | 2010 | 78 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 565 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 72 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.020 |
Why?
|
| Globosides | 1 | 2010 | 16 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 241 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 7789 | 0.020 |
Why?
|
| Glycolipids | 1 | 2010 | 58 | 0.020 |
Why?
|
| Peptide Library | 1 | 2010 | 158 | 0.020 |
Why?
|
| Radiotherapy | 2 | 2010 | 1824 | 0.020 |
Why?
|
| Risk Factors | 3 | 2014 | 17523 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1022 | 0.020 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2009 | 26 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 771 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2011 | 3154 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 501 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 709 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 68 | 0.020 |
Why?
|
| Gene Deletion | 2 | 2006 | 1442 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 508 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2010 | 65 | 0.020 |
Why?
|
| Reoperation | 2 | 2005 | 1382 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2054 | 0.020 |
Why?
|
| Spinal Canal | 1 | 2009 | 14 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 2009 | 33 | 0.020 |
Why?
|
| Tryptophan | 1 | 2010 | 127 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 2009 | 137 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2009 | 41 | 0.020 |
Why?
|
| Culture Media | 1 | 2010 | 319 | 0.020 |
Why?
|
| Phospholipids | 1 | 2010 | 177 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 633 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.020 |
Why?
|
| Proteinuria | 1 | 2009 | 155 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 231 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 261 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1077 | 0.020 |
Why?
|
| Gangliosides | 1 | 2009 | 95 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2009 | 2054 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2011 | 232 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 629 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 1248 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 342 | 0.020 |
Why?
|
| Models, Biological | 2 | 2010 | 3254 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 783 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 136 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 5710 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2009 | 173 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 515 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 170 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 2009 | 151 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5112 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4638 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 324 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 679 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 755 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 931 | 0.020 |
Why?
|
| Hypoxia | 1 | 2010 | 443 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2007 | 69 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4320 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 212 | 0.020 |
Why?
|
| Time | 1 | 2007 | 178 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2006 | 51 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 1154 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 551 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 335 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2006 | 202 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2008 | 519 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1910 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2291 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1732 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 151 | 0.020 |
Why?
|
| Chickens | 1 | 2006 | 523 | 0.020 |
Why?
|
| Everolimus | 1 | 2008 | 415 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 200 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 673 | 0.020 |
Why?
|
| Flucytosine | 1 | 2005 | 30 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 70 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 1149 | 0.020 |
Why?
|
| PAX6 Transcription Factor | 1 | 2005 | 53 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10001 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 2316 | 0.020 |
Why?
|
| S Phase | 1 | 2006 | 281 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 287 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 253 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 1904 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2005 | 134 | 0.020 |
Why?
|
| Catheterization | 1 | 2007 | 410 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2004 | 38 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2004 | 22 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 482 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 2104 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2004 | 264 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2004 | 88 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 666 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3343 | 0.010 |
Why?
|
| Infant | 2 | 2013 | 13310 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2003 | 159 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2004 | 145 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 189 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 150 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 221 | 0.010 |
Why?
|
| Cell Division | 1 | 2007 | 2489 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 2002 | 88 | 0.010 |
Why?
|
| Paresis | 1 | 2002 | 54 | 0.010 |
Why?
|
| Space Perception | 1 | 2002 | 77 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 798 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 891 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 1391 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 661 | 0.010 |
Why?
|
| Thalamus | 1 | 2002 | 132 | 0.010 |
Why?
|
| Visual Fields | 1 | 2002 | 142 | 0.010 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2004 | 285 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 1546 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2002 | 316 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 2803 | 0.010 |
Why?
|
| Attention | 1 | 2002 | 281 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 1682 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 509 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2002 | 671 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 6682 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 1265 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6869 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2002 | 1529 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2002 | 1271 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 1162 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 15694 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 1833 | 0.010 |
Why?
|
| Software | 1 | 2002 | 1321 | 0.010 |
Why?
|
| Sarcoma | 1 | 2004 | 1725 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 5767 | 0.010 |
Why?
|